Innate and Adaptive Immune Cell Cross-Talk in Lung Allergy

肺部过敏中的先天性和适应性免疫细胞交叉对话

基本信息

项目摘要

Asthma is a complex inflammatory disease thought to reflect a dysregulated immune state that is established by elevated levels of the cytokines IL-4 and IL-13 in lung tissues. Increased numbers of innate and adaptive IL-4/IL-13-expressing cells, including Th2 cells, eosinophils, basophils and mast cells are found in chronically affected lung, and elevated levels of IgE are believed to contribute to sensitivity to aeroallergens. Despite the discovery of microbial ligands for receptors that induce inflammatory T helper cells subsets, including Th1 cells and Th17 cells, few molecular markers are known which induce immune responses by the characteristic cell types involved in allergy and asthma. We have recently discovered that a common constituent associated with many allergens is capable of inducing influx of eosinophils and basophils into the lungs of mice. Further, instillation induced the accumulation of alternatively activated macrophages, which are increasingly being recognized as a critical element of allergic immunity. This project will explore the contributions by this constituent component of helminths, insects and fungal cell walls in provoking changes in dendritic cells that mediate differentiation of Th2 cells, recruitment of innate IL-4/IL-13-producing cells, induction of B cell responses leading to IgE and lgG1, and ultimately a mucosal and tissue response. Using mice with genes modified to report faithful expression of key components of Th2-associated immunity, three specific aims are proposed: 1. To assess the role of chitin as an adjuvant and as a component of a fungal extract of Aspergillus in inducing dendritic cell activation in vivo. 2. To assess the role of chitin as an adjuvant and as a component of a fungal extract of Aspergillus in inducing Th2 cells and IL-4-dependent antibody isotypes. 3. To assess the role of chitin in the induction of feedback mechanisms that limit the inflammatory process in the lungs. LAY SUMMARY: The prevalence of asthma remains extensive in the United States and other developed countries. Knowledge of precise environmental agents that contribute to asthma and that can be studied in model animal systems is incomplete. This proposal will use mice to study novel and relevant mechanisms.
哮喘是一种复杂的炎症性疾病,被认为反映了一种已建立的免疫失调状态

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard M Locksley其他文献

Richard M Locksley的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard M Locksley', 18)}}的其他基金

Epithelial chitinase and lung homeostasis
上皮几丁质酶和肺稳态
  • 批准号:
    8946156
  • 财政年份:
    2015
  • 资助金额:
    $ 33.06万
  • 项目类别:
Epithelial chitinase and lung homeostasis
上皮几丁质酶和肺稳态
  • 批准号:
    9262267
  • 财政年份:
    2015
  • 资助金额:
    $ 33.06万
  • 项目类别:
ILC2 and epithelial cell heterogeneity and self-sustaining type 2 airway niches in asthma
ILC2 和上皮细胞异质性以及哮喘中自我维持的 2 型气道生态位
  • 批准号:
    10472534
  • 财政年份:
    2012
  • 资助金额:
    $ 33.06万
  • 项目类别:
Innate helper type-2 cells in allergic lung
过敏性肺中的先天辅助2型细胞
  • 批准号:
    8395783
  • 财政年份:
    2012
  • 资助金额:
    $ 33.06万
  • 项目类别:
ILC2 and epithelial cell heterogeneity and self-sustaining type 2 airway niches in asthma
ILC2 和上皮细胞异质性以及哮喘中自我维持的 2 型气道生态位
  • 批准号:
    10681273
  • 财政年份:
    2012
  • 资助金额:
    $ 33.06万
  • 项目类别:
ILC2 and epithelial cell heterogeneity and self-sustaining type 2 airway niches in asthma
ILC2 和上皮细胞异质性以及哮喘中自我维持的 2 型气道生态位
  • 批准号:
    10226876
  • 财政年份:
    2012
  • 资助金额:
    $ 33.06万
  • 项目类别:
ILC2 and epithelial cell heterogeneity and self-sustaining type 2 airway niches in asthma
ILC2 和上皮细胞异质性以及哮喘中自我维持的 2 型气道生态位
  • 批准号:
    10006351
  • 财政年份:
    2012
  • 资助金额:
    $ 33.06万
  • 项目类别:
CD4+ T Cell Receptors in Leishmaniasis
利什曼病中的 CD4 T 细胞受体
  • 批准号:
    6983460
  • 财政年份:
    2003
  • 资助金额:
    $ 33.06万
  • 项目类别:
CD4+ T Cell Receptors in Leishmaniasis
利什曼病中的 CD4 T 细胞受体
  • 批准号:
    7147430
  • 财政年份:
    2003
  • 资助金额:
    $ 33.06万
  • 项目类别:
CD4+ T Cell Receptors in Leishmaniasis
利什曼病中的 CD4 T 细胞受体
  • 批准号:
    6757283
  • 财政年份:
    2003
  • 资助金额:
    $ 33.06万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 33.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 33.06万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 33.06万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 33.06万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 33.06万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 33.06万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 33.06万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 33.06万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 33.06万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 33.06万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了